PAUL CASSAR

Associate

Dr. Paul Cassar brings 10 years of experience in the sourcing, evaluating and funding of life sciences technologies and companies across multiple modalities and therapeutic areas. Prior to joining CTI LSF, Dr. Cassar was a Licensing and Commercialization Associate specializing in Business Intelligence at University Health Network (UHN), Canada’s top Research Commercialization Institute. While at UHN Paul advised on licensing, partnering, and financing deals for UHN assets and spinout companies including a recent $91M Series B financing to UHN spinout company, Treadwell Therapeutics. Paul’s expertise spans multiple scientific and business disciplines required for success in life science investing including market analysis and forecasting, financial modeling, intellectual property assessment, project planning and management, research and development, licensing, and company creation. Paul is dedicated to building Canada’s life sciences sector as exemplified by his previous roles as a Scientist and Business Development Manager at adMare Bioinnovations, Director of Scientific Affairs at Canada’s Stem Cell Network, and his ongoing participation on BIOTECanada’s Emerging Company Advisory Board. Dr. Cassar holds a PhD in stem cell biology and functional genomics from the Institute of Medical Science at the University of Toronto and a BSc in Pharmacology from McMaster University.